Leaf extract of Morinda lucida improves pancreatic beta-cell function in alloxan-induced diabetic rats
No Thumbnail Available
Date
2019-09-16
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis
Abstract
Chemotherapy remains the utmost treatment for Type 1 diabetes (T1D)
patients. This however, predisposes the patients to a wide range of serious
complications, thus, the need for alternative therapeutic agents that target
pancreatic β-cell function. This study investigated the effects of aqueous leaf
extract of M. lucida (MLE) on β-cell dysfunction and atherogenic dyslipidaemia
in alloxan-induced T1D in rats. Twenty-five Wister rats (156- 168g) were
randomly divided into normal, diabetic, diabetic + glibenclamide (5 mg/kg),
diabetic + 120 mg/kg MLE and diabetic + 240 mg/kg MLE groups (n = 5/
group). Treatments were via oral route for 14 days. Our findings revealed that,
120 mg/kg MLE significantly reduced hyperglycaemia, improved insulinaemia
as well as β-cell function, and attenuated weight loss in alloxan-induced
diabetic rats. The extract also attenuated (p < 0.05) atherogenic dyslipidaemia
and malondialdehyde. The activities of the extract compared favourably with
glibenclamide. This study suggested that, hypoglycaemic and mitigating
effects of aqueous leaf extract of M. lucida on atherogenic dyslipidaemia
and pancreatic β-cell dysfunction were through reduction in lipid peroxidation. The extract may therefore represent an effective source of novel drugs
against TID and cardiovascular diseases. Further study is recommended, to
explore the extract’s mechanism of oxidative repair
Description
Keywords
Type 1 diabetes, β-cell function, lipid peroxidation, weight loss, Morinda lucida, extract